The Cardiology Bioengineering Laboratory, located in the Johns Hopkins Hospital, focuses on the applications of advanced imaging techniques for arrhythmia management. The primary limitation of current fluoroscopy-guided techniques for ablation of cardiac arrhythmia is the inability to visualize soft tissues and 3-dimensional anatomic relationships.
Implementation of alternative advanced modalities has the potential to improve complex ablation procedures by guiding catheter placement, visualizing abnormal scar tissue, reducing procedural time devoted to mapping, and eliminating patient and operator exposure to radiation.
Active projects include
• Physiological differences between isolated hearts in ventricular fibrillation and pulseless electrical activity
• Successful ablation sites in ischemic ventricular tachycardia in a porcine model and the correlation to magnetic resonance imaging (MRI)
• MRI-guided radiofrequency ablation of canine atrial fibrillation, and ...diagnosis and intervention for arrhythmias
• Physiological and metabolic effects of interruptions in chest compressions during cardiopulmonary resuscitation
Henry Halperin, MD, is co-director of the Johns Hopkins Imaging Institute of Excellence and a
professor of medicine, radiology and biomedical engineering. Menekhem M. Zviman, PhD is the laboratory manager. view more
Our research focuses at the nexus of HIV and alcohol and other substance use. We examine epidemiological aspects of HIV and alcohol use/other drug use among persons with HIV (PWH), and work on the adaptation and testing of person and computer-delivered interventions for unhealthy alcohol use, particularly among women.
Research in the Hanan Aboumatar Lab focuses on advancing patient-centered outcomes through improved patient and family involvement. We also focus on multilevel methods to increase the patient-centered focus of care delivery. Recent research examined the impact of a quality-improvement intervention on patient involvement in primary care and treatment with respect and dignity in intensive care.
Work in the Hsin-Chieh Yeh Lab focuses on clinical trials and cohort studies of diabetes, obesity and behavioral intervention, cancer and hypertension. Recent investigations have focused on novel risk factors and complications related to obesity and type 2 diabetes, particularly lung function, smoking and cancer. We recently co-led a randomized clinical trial of tailored dietary advice for consumption of dietary supplements to lower blood pressure and improve cardiovascular disease risk factors in hypertensive urban African Americans.
Research in the Jeanne Clark Lab covers a wide range of fields, employing various research techniques, methods and procedures to generate and disseminate the knowledge required to prevent disease and its consequences. Our most recent research program, Look AHEAD, focuses on the health of overweight volunteers with type 2 diabetes. We are examining the long-term effects of an intensive lifestyle intervention program designed to achieve and maintain weight loss by decreased caloric intake and increased physical activity.
Work in the Kristin Riekert Lab focuses on methods for improving health care quality and delivery, particularly among underserved and disadvantaged populations. Our research covers a range of important topics, including health beliefs, treatment adherence, doctor-patient communication, self-management interventions, mobile health initiatives, health disparities and patient-reported outcome methodology. We also work with the National Institutes of Health on multiple intervention trials focused on improving adherence and health outcomes in asthma, chronic kidney disease, cystic fibrosis (CF), sickle cell disease and secondhand smoke reduction.
Research in the Larry Chang Lab focuses on innovative, multidisciplinary and pragmatic approaches to impacting the HIV/AIDS pandemic. Our research investigates ways to improve HIV/AIDS care in low- and middle-income settings through strategies that include quantitative methods, qualitative methods, community-based trial designs, and behavioral science and economic evaluations. In addition, we research mobile technologies for health (mHealth) strategies for improving global public health and clinical care, including novel applications for intimate-partner violence intervention, dengue surveillance, and HIV care, surveillance and prevention.
Work in the Sean Berenholtz Lab focuses on patient safety, ICU care, quality health care and evidence-based medicine. Two notable and successful projects include the National On The Cusp: Stop BSI project, which was implemented in 47 states with the goal of eliminating bloodstream infections, and the Agency for Healthcare Research and Quality (AHRQ)-funded Keystone ICU project, which improved communication and teamwork and reduced hospital-acquired infections in more than 100 ICUs in Michigan. One recent study focused on ventilator-associated pneumonia (VAP), one of the most common type of health care-associated infections in the ICU. Existing VAP prevention intervention bundles vary widely on the interventions, but our research team described a structured approach for developing a new VAP prevention bundle.
Dr. Yegnasubramanian directs a Laboratory of Cancer Molecular Genetics and Epigenetics at the Sidney Kimmel Comprehensive Cancer Center (SKCCC), and is also the Director of the SKCCC Next Generation Sequencing Center.
Our lab research is focused on understanding the complex interplay between genetic and epigenetic alterations in carcinogenesis and disease progression, and to exploit this understanding in developing novel biomarkers for diagnosis and risk stratification as well as in identifying targets for therapeutic intervention.
The goals of the Translational neurobiology Laboratory are to understand the pathogenesis and cell death pathways in neurodegenerative disorders to reveal potential therapeutic targets for pharmaceutical intervention; to investigate endogenous survival pathways and try to induce these pathways to restore full function or replace lost neurons; and to identify biomarkers to mark disease function or replace lost neurons; and to identify biomarkers to mark disease progression and evaluate therapeutics.
Our research projects focus on models of Huntington's disease and Parkinson's disease. We use a combination of cell biology and transgenic animal models of these diseases.
We are exploring whether anodal tDCS when administered in combination with spelling, naming, or working memory therapy can improve language performance of PPA and MCI participants at least in the short term more than behavioral therapy alone. We are also investigating whether and how tDCS alters the neuropeptide signature in participants with PPA and MCI. We use proton magnetic resonance spectroscopy (1H-MRS) to monitor neuropeptide concentrations at the areas of stimulation. We hypothesize that tDCS will stabilize the decline of specific neuropeptides, but only in those areas of the brain where tDCS effectively results in more efficient gains in language compared to language therapy alone (with sham tDCS). Study results may help optimize future intervention in individuals with PPA and MCI by providing treatment alternatives in a neurodegenerative condition with no proven effective treatment. A better understanding of the therapeutic and neuromodulatory effects of tDCS in PPA and MCI w...ill offer insight into ways of impeding neurodegeneration that may improve quality of life for individuals with PPA and MCI and may provide insights into the mechanisms of this treatment for augmenting therapy for stroke as well.view more
The lab currently focuses on identifying genetic alterations in cancer affecting sensitivity and resistance to targeted therapies, and connecting such changes to key clinical characteristics and novel therapeutic approaches. We have recently developed methods that allow noninvasive characterization of cancer, including the PARE method that provided the first whole genome analysis of tumor DNA in the circulation of cancer patients. These analyses provide a window into real-time genomic analyses of cancer patients and provide new avenues for personalized diagnostic and therapeutic intervention.